NeurologyOnline.net

Neurology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Among patients with a transient ischemic attack ( TIA ) or minor ischemic strokes, those with ipsilateral atherosclerotic stenosis of cervicocranial vasculature have the highest risk of recurrent vasc ...


A study has investigated the hypothesis that strokes occurring in patients with COVID-19 have distinctive features. Researchers have performed a systematic search resulting in 10 studies reporting ...


Insomnia with objective short sleep duration has been previously associated with adverse cardiometabolic health outcomes as well as poorer cognitive performance in otherwise noncognitively impaired ad ...


Siponimod ( Mayzent ) is a selective sphingosine 1-phosphate receptor ( S1P1 and S1P5 ) modulator, approved in the USA for treatment of relapsing forms of multiple sclerosis ( MS ), including clinical ...


Thalamic volume ( TV ) change is a measure of disease progression in relapsing multiple sclerosis ( RMS ); the relationship between thalamic volume and quality of life ( QOL ) has not been well charac ...


Living near major roads or highways is linked to higher incidence of dementia, Parkinson's disease, Alzheimer's disease and multiple sclerosis, suggests new research published in the journal Environme ...


Longer-term data from the phase III open-label extension studies of OPERA I, OPERA II and ORATORIO have shown that patients who were treated with Ocrelizumab ( Ocrevus) continuously for six years or m ...


Venous percutaneous transluminal angioplasty ( vPTA ) in patients with multiple sclerosis ( MS ) and chronic cerebrospinal venous insufficiency ( CCSVI ) have shown contradictory results. The aim of ...


Tthe FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) an oral medication for the acute treatment of migraine, with or without aura, in adults. Reyvow has a unique mechani ...


A large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor ( TNF ) blocking agent reduc ...


Positive results for Ofatumumab ( OMB157 ) from the phase III ASCLEPIOS I and II studies were announced. In both head-to-head studies, Ofatumumab has demonstrated superiority over Teriflunomide ( Auba ...


People who report an elevated number of depression symptoms may be more likely to have a stroke years later than people with no depression symptoms or a low number of depression symptoms, according to ...


Current guidelines recommend lowering cholesterol for heart disease risk reduction. New findings have indicated that if cholesterol dips too low, it may boost the risk of hemorrhagic stroke. Over a ...


Ocrelizumab ( Ocrevus ) is a CD20+ B cell-selective monoclonal antibody approved for treatment of relapsing multiple sclerosis ( RMS ) and primary progressive multiple sclerosis ( PPMS ). Ocrelizum ...


Ocrelizumab ( Ocrevus ) is an infusible humanized monoclonal antibody that selectively depletes CD20+ B cells. Infusion-related reactions ( IRRs ) were summarized from the OPERA I, OPERA II, and ORA ...